Oncology News Central (ONC)Rapidly Changing Landscape in Ovarian Cancer Raises Questions About Newly Updated Guidelines

✅ Guideline Update

The ESMO update to its 2023 epithelial ovarian cancer guidelines expanded first-line PARP inhibitor options and added mirvetuximab soravtansine for platinum-resistant recurrent disease. U.S. clinicians face meaningful regulatory divergence: rucaparib lacks FDA frontline approval, and niraparib’s U.S. label is restricted to HRD-positive tumors only.

Clinical Considerations

• ESMO now recommends rucaparib, olaparib, or niraparib as first-line maintenance across BRCA-mutated, HRD-positive, and HRD-negative subgroups — with bevacizumab combinations available in select groups
• Mirvetuximab soravtansine enters ESMO guidance for platinum-resistant high-grade serous ovarian cancer with high FRα expression after 1–3 prior lines; FDA granted full approval in March 2024 with a boxed ocular toxicity warning
• Post-publication FDA approvals of pembrolizumab plus paclitaxel (February 2026) and relacorilant plus nab-paclitaxel (March 2026) for platinum-resistant disease are not captured in the ESMO update
• PARP inhibitors share mechanism but differ substantially in dose, schedule, and metabolism — class-level substitution is not appropriate

Practice Applications

• Recognize that U.S. prescribing authority diverges from ESMO recommendations on rucaparib frontline use and niraparib eligibility
• Integrate mirvetuximab soravtansine into recurrent disease counseling for high FRα-expressing tumors; monitor for ocular toxicity per FDA label
• Consider pembrolizumab plus paclitaxel and relacorilant plus nab-paclitaxel as current platinum-resistant options not reflected in ESMO guidance
• Avoid applying ESMO PARP inhibitor recommendations interchangeably across agents without reviewing individual drug labels